NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is hosting a research and development (R&D) day in New York City today with key opinion leaders (KOLs), to highlight the company’s CNS product candidate AXS-05 (bupropion and dextromethorphan) and unmet needs in depression, agitation associated with Alzheimer’s disease, and nicotine dependence.
“We are honored to host such a distinguished group of thought leaders from a variety of CNS disciplines to discuss the treatment landscape for these important CNS conditions,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “We are excited about the unique pharmacology of AXS-05 and its prospects for addressing the unmet needs in all three of these indications. We look forward to announcing the results of the planned interim analyses for our Phase 3 trial in treatment resistant depression and our Phase 2/3 trial in agitation associated with Alzheimer’s disease this year.”
The R&D day will feature presentations by Stephen M. Stahl, MD, PhD, DSc (Adjunct Professor of Psychiatry, University of California San Diego); Maurizio Fava, MD (Executive Vice Chair of the Department of Psychiatry and Executive Director of the Clinical Trials Network and Institute at Massachusetts General Hospital); Marc Agronin, MD (Vice President of Behavioral Health and Clinical Research at Miami Jewish Health); and James Davis, MD (Medical Director of the Duke Center for Smoking Cessation and Associate Professor of Medicine, Duke University School of Medicine); as well as by Axsome management.
A live and archived webcast of the event, with slides, can be accessed on the investor page of Axsome’s website at www.axsome.com starting at 12:00pm EST.